-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On Kalaris Therapeutics with Buy Rating, Announces Price Target of $19

Benzinga·12/23/2025 12:41:13
Listen to the news
Chardan Capital analyst Daniil Gataulin initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Buy rating and announces Price Target of $19.